Aktienanalyse zu Mesa Laboratories Inc (MLAB)MLABMesa Laboratories Inc

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).

Mesa Laboratories Inc is currently a hold. The stock closed at $127.51, showing a year-to-date change of +60.53%, which indicates strong performance over the year. However, the RSI is at 40.74, suggesting it is nearing oversold territory, which could indicate a potential rebound. The forward P/E ratio of 34.48 is high, reflecting strong growth expectations, but the recent earnings report showed a revenue miss, which is a concern. The main risk is the company’s recent volatility, with a 19.5% drop following the Q4 earnings report, indicating uncertainty in future performance.

2 analysts cover MLAB: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.